Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009

This report considers the population benefits, value and cost-effectiveness of needle and syringe programs.

Page last updated: 2009

Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009 (html)
Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009 (PDF 3969 KB large file)

The same publication in smaller sections:

Cover pages (PDF 206 KB)
Executive summary (PDF 196 KB)
Introduction and brief review of prior studies (PDF 236 KB)

Epidemiological impact of NSPs on Australian IDUs (PDF 613 KB large file)
Economic evaluation of Australia's NSPs (PDF 248 KB)
Epidemiological and economic evaluation of NSPs in the Australian Capital Territory (PDF 331 KB)
Epidemiological and economic evaluation of NSPs in New South Wales (PDF 354 KB)
Epidemiological and economic evaluation of NSPs in Northern Territory (PDF 367 KB)
Epidemiological and economic evaluation of NSPs in Queensland (PDF 324 KB)
Epidemiological and economic evaluation of NSPs in South Australia (PDF 361 KB)
Epidemiological and economic evaluation of NSPs in Tasmania (PDF 316 KB)
Epidemiological and economic evaluation of NSPs in Victoria (PDF 372 KB)
Epidemiological and economic evaluation of NSPs in Western Australia (PDF 348 KB)
Epidemiological and economic evaluation of NSPs for Aboriginal and Torres Strait Islanders (PDF 233 KB)

Discussion (PDF 156 KB)
References (PDF 195 KB)
Appendix A: Development of epidemic mathematical transmission model (PDF 550 KB large file)
Appendix B: Input data and assumptions for epidemic model (PDF 1139 KB large file)
Appendix C: Healthcare costs (PDF 126 KB)
Appendix D: Productivity losses and gains (PDF 117 KB)
End page (PDF 134 KB)

If you are unable to download the PDF document, please contact drugtreatment@health.gov.au.

Page last reviewed: 18 April 2011